Grants
You have a project that fits the PRIM mission: go to our grant page for the procedure
Read more
Latest News
New call for proposals / Nouvel appel à projets
Deadline 13 Dec 2011 Procedure details and calendar
Seminar Pr Greaney : 19th Oct. 2011 USTL Read More
PRIM at the Science Fair : Oct 13-16th
Seminar Pr R. Dodd (ICSN) 11th Oct.
Read More
New article about PRIM in Le Nouvel Observateur Read More
Mailing list
Keep informed on Scientific Meetings and grant filing.
Rester informé sur les manifestations scientifiques et les appels d'offre. Registration
|
List of the scientific projects that received grants
-
-
PRIM-TGR5: TGR5 bile acid receptors: Therapeutic targets for the metabolic syndrome – From chemistry to biological effects. (2008/-)
Coordinators:
- INSERM U545 : Bart Staels
- INSERM U761 : Julie Charton
Mission:
Discovery and optimization of TGR5 ligands as pharmacological tools and potential therapeutic agents for the treatment of diseases linked to cholesterol and bile acid metabolism and homeostasis. Feeding the drug discovery pipeline in the therapeutic area of metabolic syndrome and its complications.
-
PRIM-CB2: Development of CB2 agonists and their applications in intestinal inflammatory chronic diseases.(2008)
Coordinator:
- ICPAL EA2692 : Regis Millet
Mission:
This project aims at exploring CB2 agonists for the treatment of chronic inflammatory bowel diseases (IBD).
...
-
PRIM-SP: Privileged structures - Natural-like compounds from keto-acids.(2008)
Coordinators:
- CNRS UMR8010 : Lydie Pelinski Lille2
- EA1043 : Nicolas Lebegue
- INSERM U761 : Guillaume Laconde, Rebecca Déprez-Poulain
Mission :
The project aims at designing and synthesizing chemical libraries to enrich the regional library with privileged structures inspired from natural products.
-
PRIM-BOOST INH: Drug-induced hypersensibilization of M. tuberculosis to the first line drug Isoniazid. (2008)
Coordinators:
- INSERM U629 : Alain Baulard
- INSERM U761 : Nicolas Willand
Mission:
With one third of the world population infected, more than 9 million people developing the active disease and 2 million deaths each year, Tuberculosis (TB) remains a worldwide health threat.1 Attempts to treat TB are hindered by the increasing spread of multidrug-resistant (MDR) and extensively drug-resistant (...
-
PRIM-GSK3: GSK3b inhibitors as treatment for Alzheimer disease. (2008)
Coordinators:
- INSERM U422 : Luc Buée
- Targeon : Hugues Bienaymé
- INSERM U761 : Benoit Déprez
Mission:
- Identification of lead compounds active in vitro (enzymatic and phenotypic screen) with suitable early ADME parameters.
- Identification of Optimized lead compounds with good drugability, demonstrated in vivo activity and suitable PK and toxicity param...
-
PRIM-ADME: Bridging the gap between in vitro optimisation and proof-of-concept in vivo. (2008)
Coordinators:
- INSERM U761 : Florence Leroux
- JE2491 : Juergen Siepmann
Mission:
Maximise the output of in vitro compound optimisation and enable the interpretation of in vivo data and optimise the...
-
PRIM-CAIRICOL: Potentialisation of the activity of topoisomerase I inhibitors by carbonic anhydrase IX inhibitors: treatment of colorectal cancers.(2009/-)
Coordinators:
- EA4034 : Jean-François Goossens
- CHR-Oscar Lambret : Amélie Lansiaux
Mission:
Potentialisation of the activity of topoisomerase I inhibitors by inhibitors of carbonic anhydrase type IX : applications to the treatment of colorectal cancers.
<...
-
PRIM-AMBIO: Enhancement of bioavailability of bioactive compounds poorly soluble by extrusion.(2009/-)
Coordinators :
- JE 2491 : Juergen Siepman
- INSERM U761 : Benoit Deprez
Mission :
The aim of this proposal is to enforce the PRIM technology platform “early formulation/administration/PK analysis” with a specific equipment allowing for the preparation of monolithic drug solutions in hydrophilic polymers: a hot-melt extruder.
|
